Spine Biologics Market 2026 Growing Worldwide By Best Key players- Stryker; Orthofix International N.V.; K2M Inc.; Exactech Inc.; Wright Medical Technology Inc.; DePuy Synthes Companies; Zimmer Holding Inc.; Nuvasive Inc.; Medtronic Inc.

 

The global spine biologics market size is expected to reach USD 2.5 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.2% CAGR over the forecast period. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities. Spine biologics consists of biomaterials that can be used in the treatment of degenerative disc diseases, spinal cord injuries, and bone fusion surgeries. The usage of these products has always been crucial in spine surgery. Spinal fusion is a procedure used to correct defects in small bones (vertebrae) in the spine.

Surgeons are using advanced biological mechanisms for the treatment of spine deformities, such as extreme lateral interbody fusion and direct lateral interbody fusion. According to a research article published in BMC Musculoskeletal Disorders in 2018, the study concluded that the minimally invasive approach to lateral interbody fusion technology has the benefit of less injury and swift recovery post-surgery. This is an effective and safe treatment for spine disorders such as thoracic and lumbar spinal tuberculosis. Advancements in biomaterials make it easy for surgeons to treat people suffering from spine-related disorders such as disc degeneration and scoliosis.

To Request Sample Copy of this report, click the link:

https://www.grandviewresearch.com/industry-analysis/spine-biologics-market/request/rs1

Industry players have been focusing on the development of technologically advanced and cost-effective products to gain a competitive advantage. For instance, in 2018, NuVasive expanded its biologics business line with the launch of AttraX Scaffold. Collaborations, acquisitions, and mergers are also part of companies’ growth strategies. In May 2016, Stryker procured Orthovita Inc., a maker of biologics used in spine surgery, for USD 316 million to strengthen its spine biologics and implants capabilities.

Further key findings from the report suggest:

• Many clinicians consider spinal allografts as the gold standard for spinal fusion. The use of biologics influences surgical outcomes as it helps in improving fusion rates and reducing pain. This driven the segment to account for the dominant revenue share
• Hospitals held the leading share in terms of end use in 2018 owing to availability of highly skilled professionals and increasing number of spine surgeries performed. Ambulatory Surgery Centers (ASC), on the other hand, are anticipated to witness lucrative growth over the forecast period
• North America captured the largest share in the market in 2018, owing to presence of well-established healthcare infrastructure, high awareness among surgeons pertinent to bone graft procedures, and availability of favorable reimbursement policies
• Asia Pacific is anticipated to show significant growth through 2026. Booming medical tourism industry offering advanced healthcare services at affordable costs is the key factor driving the regional spine biologics market
• Some of the key companies are Stryker; Orthofix International N.V.; K2M Inc.; Exactech Inc.; Wright Medical Technology Inc.; DePuy Synthes Companies; Zimmer Holding Inc.; Nuvasive Inc.; and Medtronic Inc. Strategic acquisitions and presence of new entrants are making the market immensely competitive.

The market is highly fragmented due to the presence of many leading players operating globally and occupying a significant share. The market is characterized by high competition based on price, product differentiation, and low cost of technology. It is also marked by an increased focus on the development of innovative products and a successful track record of mergers and acquisitions. Major manufacturers, raw material suppliers, and machinery manufacturers have been working in tandem to research, develop, and innovate new products within the field of spine biologics.

Some of the prominent players that fuel market growth are Stryker; Orthofix Holdings, Inc.; NuVasive, Inc.; K2M Inc.; DePuy Synthes; Wright Medical Group N.V.; Exactech, Inc.; Zimmer Biomet; Arthrex, Inc.; Medtronic Inc.; Organogenesis; and Lattice Biologics Ltd. In August 2018, Aziyo Biologics and RTI surgical Holdings, Inc., a global surgical implant company, signed an agreement wherein Aziyo provided its product ViBone (a bone repair product designed to perform autografts) to RTI surgical to be used in a variety of orthopedic procedures. This agreement was focused on exclusive distribution in the U.S. Such collaborations by major players will lend the market a significant boost.

Grand View Research has segmented the global spine biologics market report on the basis of product, end use:

Spine Biologics Product Outlook (Revenue, USD Million, 2014 - 2026)

• Spinal Allografts
• Machined Bones Allograft
• Demineralized Bone Matrix
• Bone Graft Substitutes
• Bone Morphogenetic Proteins
• Synthetic Bone Grafts
• Cell-based Matrix

Spine Biologics End-use Outlook (Revenue, USD Million, 2014 - 2026)

• Hospitals
• Ambulatory Surgical Centers
• Others

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.